SCILEX HOLDING COMPANY - COMMON STOCK

Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool

09 Apr 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend

27 Mar 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients

21 Mar 2024 09:30:29 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed

20 Mar 2024 11:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®

20 Mar 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation

19 Mar 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

18 Mar 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.

15 Mar 2024 14:45:35 By Nasdaq GlobeNewswire

Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement

15 Mar 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering

05 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024

05 Mar 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

04 Mar 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024

02 Mar 2024 15:25:17 By Nasdaq GlobeNewswire

Scilex Holding Company Announces $10 Million Bought Deal Offering

29 Feb 2024 17:32:38 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA® in Most of Their Stores Throughout the U.S.

28 Feb 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)

27 Feb 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement

26 Feb 2024 16:53:22 By Nasdaq GlobeNewswire

Scilex Holding Company Announces that ZTlido® Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met

26 Feb 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

20 Feb 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

08 Jan 2024 09:00:00 By Nasdaq GlobeNewswire